Mistletoe (Viscum) has been used as an adjunct in inoperable cancer treatment for the past several decades, but it is difficult to find providers who are able to provide the service, and it is difficult to obtain the medication. Doses are calculated according to the patient’s sex, type of cancer, and body temperature. The medication is delivered by subcutaneous injections in the vicinity of the tumor location, usually three times weekly. This medication is contraindicated in patients with dysmenorrhea, epilepsy, migraines, and in pregnancy. It is also contraindicated in patients after brain concussion, during acute influenza illness, or other acute febrile condition.
Patient benefits include improved immune system function, improved sense of self, increased assertiveness, invigoration, more meaningful social interactions, and improved pain tolerance.
Patients receiving Viscum are asked to measure oral temperatures at specific times daily, and record the temperatures on a chart. Oral temperature should be measured two hours and four hours after, each Viscum injection, and recorded on the temperature chart. Additionally, patients should measure and record oral temperature every morning between 6-8 AM, and every evening between 5-7 PM.
Two to four hours after injection, the oral temperature should be 0.5 to 0.9 degrees F. higher than the body temperature as compared to body temperatures taken at the same time of day on injection-free days. A rise of temperature to as high as 100.4 is still considered to be a favorable reaction, as long as no shivering or ill feelings occur, and as long as the temperature reverts to normal on the following day. Temperature elevations that do not subside, need to be evaluated and treated, and further Viscum doses are held pending that evaluation and treatment, and pending return to normal temperature.